Creo Medical Group plc

("Creo", the "Company" or the "Group")

Posting of 2024 Annual Report and Accounts

and

Notice of Annual General Meeting

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the Annual Report and Accounts for the year ended 31 December 2024 and the Notice of the Company's Annual General Meeting ("AGM") have now been published on the Company's website at https://www.creomedical.com/en/investors/reports-and-presentations, with hard copies being posted to those shareholders who have not elected to receive electronic communication from the Company.

The AGM will be held on Thursday, 26 June 2025 at 10:00am at the offices of Osborne Clarke LLP at Halo, Counterslip, Bristol BS1 6AJ, and will consider the Resolutions set out in the Notice of AGM. The Company's CEO, Craig Gulliford, will make a short presentation at the meeting. No new material information will be included within the presentation.

Shareholders are encouraged to vote by proxy at the AGM, which can be done:

·    by completing, signing the Form of Proxy and returning it to Equiniti; or

·    in the case of CREST members, by utilising the CREST electronic proxy appointment service.

Proxy votes must be received no later than 10:00am on 24 June 2025. All voting at the AGM will be conducted by a poll. Shareholders are recommended to appoint the Chair of the meeting as their proxy rather than a named person, as any such other person may not be permitted to attend the AGM in the event of unforeseen circumstances (e.g. illness).

For further information please contact: 

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com